The overexpression of neurotensin subtype 1 receptor (NTS1R) in prostate cancer has also been reported in a number of studies, providing the opportunity for double GRPR/NTS1R-targeting [27,28,29,30,31,32]. This evidence concerns the gene GRPR and prostate carcinoma.